↓ Skip to main content

Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators

Overview of attention for article published in Health Research Policy and Systems, June 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter
14 X users

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
155 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators
Published in
Health Research Policy and Systems, June 2012
DOI 10.1186/1478-4505-10-18
Pubmed ID
Authors

Rahim Rezaie, Anita M McGahan, Sarah E Frew, Abdallah S Daar, Peter A Singer

Abstract

Biopharmaceutical innovation has had a profound health and economic impact globally. Developed countries have traditionally been the source of most innovations as well as the destination for the resulting economic and health benefits. As a result, most prior research on this sector has focused on developed countries. This paper seeks to fill the gap in research on emerging markets by analyzing factors that influence innovative activity in the indigenous biopharmaceutical sectors of China, India, Brazil, and South Africa. Using qualitative research methodologies, this paper a) shows how biopharmaceutical innovation is taking place within the entrepreneurial sectors of these emerging markets, b) identifies common challenges that indigenous entrepreneurs face, c) highlights the key role played by the state, and d) reveals that the transition to innovation by companies in the emerging markets is characterized by increased global integration. It suggests that biopharmaceutical innovators in emerging markets are capitalizing on opportunities to participate in the drug development value chain and thus developing capabilities and relationships for competing globally both with and against established companies headquartered in developed countries.

X Demographics

X Demographics

The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 155 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Canada 1 <1%
Brazil 1 <1%
Unknown 152 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 33 21%
Student > Bachelor 21 14%
Student > Ph. D. Student 20 13%
Researcher 17 11%
Student > Postgraduate 11 7%
Other 27 17%
Unknown 26 17%
Readers by discipline Count As %
Business, Management and Accounting 25 16%
Medicine and Dentistry 22 14%
Social Sciences 22 14%
Pharmacology, Toxicology and Pharmaceutical Science 12 8%
Agricultural and Biological Sciences 11 7%
Other 36 23%
Unknown 27 17%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2013.
All research outputs
#3,694,658
of 23,301,510 outputs
Outputs from Health Research Policy and Systems
#524
of 1,231 outputs
Outputs of similar age
#25,240
of 168,187 outputs
Outputs of similar age from Health Research Policy and Systems
#4
of 8 outputs
Altmetric has tracked 23,301,510 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,231 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.1. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,187 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.